A Phase 1 Open-label Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Go Back to All Clinical Trials

A Phase 1 Open-label Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Relapsed/refractory Acute Myeloid Leukemia (aml)
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Patient has a confirmed diagnosis Relapsed/Refractory Acute Myeloid Leukemia (AML). 2) Patient has received, and has progressed, recurred, or is intolerant of approved therapeutic options that are available, or declines treatment with these therapies. 3) Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 2.

You may not be eligible for this study if the following are true:

1) Diagnosis of acute promyelocytic leukemia (APL). 2) Active central nervous system (CNS) leukemia. 3) Isolated extramedullary relapse.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies